Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

BIOENGINEER.ORG
bioengineer.org > antibody-drug-combination-falls-short-in-first-line-pd-l1-high-metastatic-lung-cancer-trial

Antibody-Drug Combination Falls Short in First-Line PD-L1-High Metastatic

8+ hour, 3+ min ago   (650+ words) A closely watched Phase 3 clinical trial has delivered a sobering verdict on one of the most anticipated treatment strategies in lung cancer medicine....

BIOENGINEER.ORG
bioengineer.org > scientists-flip-the-drug-discovery-pipeline-to-put-human-biology-first-in-cardiovascular-research

Scientists Flip the Drug Discovery Pipeline to Put Human Biology First in

8+ hour, 37+ min ago   (704+ words) Cardiovascular medicine is quietly undergoing a structural rethink, and the change begins with the order of operations....

BIOENGINEER.ORG
bioengineer.org > ai-that-learns-the-rules-symbolic-neural-generators-design-new-drug-candidates

AI That Learns the Rules: Symbolic Neural Generators Design New Drug

9+ hour, 10+ min ago   (90+ words) Artificial intelligence has become an increasingly powerful tool in the search for new medicines, but a persistent problem has haunted the field: neural networks that invent molecules are remarkably creative yet notoriously unreliable. They can propose chemical structures that look…...

BIOENGINEER.ORG
bioengineer.org > bispecific-antibody-meets-antibody-drug-conjugate-in-promising-small-cell-lung-cancer-trial

Bispecific Antibody Meets Antibody-Drug Conjugate in Promising Small Cell

11+ hour, 39+ min ago   (770+ words) Small cell lung cancer has long been one of the most difficult malignancies to treat, marked by aggressive growth, early dissemination and a stubborn tendency to develop resistance to standard therapies....

BIOENGINEER.ORG
bioengineer.org > plant-compound-diosgenin-emerges-as-powerful-computational-anti-cancer-candidate

Plant Compound Diosgenin Emerges as Powerful Computational Anti-Cancer

16+ hour, 16+ min ago   (698+ words) Cancer remains one of the most formidable health challenges of the modern era, claiming millions of lives each year despite decades of therapeutic advances....

BIOENGINEER.ORG
bioengineer.org > polyubiquitin-repositioning-reshapes-pathological-tau-fibril-structures-in-dementia

Polyubiquitin Repositioning Reshapes Pathological Tau Fibril Structures in

16+ hour, 48+ min ago   (668+ words) The pathological proteins that accumulate in the aging human brain are not amorphous debris. They are highly ordered molecular assemblies, and their precise atomic architecture can determine which neurodegenerative disease a patient develops, how fast it progresses, and how it…...

BIOENGINEER.ORG
bioengineer.org > beyond-kras-g12c-new-drug-wave-targets-once-undruggable-cancer-driver

Beyond KRAS G12C: New Drug Wave Targets Once-Undruggable Cancer Driver

17+ hour, 46+ min ago   (584+ words) KRAS has long been the most notorious villain in cancer genetics. The gene, formally known as Kirsten rat sarcoma viral oncogene homolog, is mutated in nearly all pancreatic ductal adenocarcinomas, a large share of colorectal cancers, and a significant fraction…...

BIOENGINEER.ORG
bioengineer.org > antibody-drug-conjugate-hits-recommended-phase-3-dose-in-egfr-mutated-lung-cancer

Antibody-Drug Conjugate Hits Recommended Phase 3 Dose in EGFR-Mutated Lung

20+ hour, 59+ min ago   (832+ words) An investigational antibody-drug conjugate that simultaneously targets two of the most important growth-driving proteins in lung cancer has delivered encouraging clinical results in patients whose tumors had already resisted modern targeted therapy, according to data presented at the International Association…...

BIOENGINEER.ORG
bioengineer.org > ruxolitinib-shows-stronger-response-in-primary-than-secondary-hlh-meta-analysis-finds

Ruxolitinib Shows Stronger Response in Primary Than Secondary HLH,

21+ hour, 32+ min ago   (632+ words) Hemophagocytic lymphohistiocytosis is one of the most feared syndromes in medicine, a runaway immune firestorm in which the body’s own scavenger cells turn against blood cells and organs, and it can kill within weeks if untreated....

BIOENGINEER.ORG
bioengineer.org > scientists-discover-how-a-widely-used-cancer-drug-is-made-in-nature

Scientists Discover How a Widely Used Cancer Drug Is Made in Nature

21+ hour, 58+ min ago   (558+ words) For six decades, one of medicine’s most important anticancer drugs has kept a remarkable secret. 5-Azacytidine, a nucleoside analogue used to treat myelodysplastic syndrome, a group of blood cancers, was first synthesized in a laboratory in the 1960s and only later…...